Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2018 Sep;16(9):1092-1106. doi: 10.6004/jnccn.2018.0073.

Chimeric Antigen Receptor T-Cell Therapy.

Author information

1
National Comprehensive Cancer Network
2
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
3
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
4
Massachusetts General Hospital Cancer Center
5
City of Hope Comprehensive Cancer Center
6
American Society of Blood and Marrow Transplantation
7
University of Colorado Cancer Center
8
University of Washington/Seattle Cancer Care Alliance
9
Dana-Farber/Brigham and Women’s Cancer Center
10
Fox Chase Cancer Center
11
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
12
Memorial Sloan Kettering Cancer Center
13
Moffitt Cancer Center
14
The University of Texas MD Anderson Cancer Center

Abstract

Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.

PMID:
30181421
DOI:
10.6004/jnccn.2018.0073

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center